Streetwise Reports' Article Archives — June 2024 back to current month (8)
California Biotech Reports Positive Phase 3 Results (06/25/2024)
"Along with the significantly lower pill burden compared to other phosphate binders, we believe the superior tolerability may be attributable to OLC's nanoparticle technology," noted an H.C. Wainwright & Co. research note, regarding Unicycive Therapeutics Inc.'s (UNCY:NASDAQ) trial of oxylanthanum carbonate (OLC) for the treatment of hyperphosphatemia in chronic kidney disease (CKD) patients.
Major New Contract Marks Significant Milestone for Counter-Drone Tech Co. (06/24/2024)
DroneShield Ltd. (DRO:ASX; DRSHF:OTC) has announced a significant new contract valued at AU$4.7 million from a non-government Swiss international customer. Find out why this is a major milestone for the company.
Chicago Alt. Medicine Co. Announces US$50M Share Repurchase Program (06/18/2024)
In a Roth MKM research note, analyst Nick Anderson noted that Verano Holdings Corp. (VRNO:CSE; VRNOF:OTCQX) was well-positioned to generate increasing cash flow.
Clean Tech Subsidiary Finds Manufacturer for Wound Solution (06/14/2024)
BioLargo Inc. (BLGO:OTCQB) announced that subsidiary Clyra Medical Technologies Inc. has selected a company to support the manufacturing of its medical products, including its surgical wound irrigation solution, Bioclynse. See why one nonprofit group says the rate of healthcare-associated infections has remained high since the pandemic.
Is This Pharma Co. the Next Eli Lilly? (06/11/2024)
Nervgen Pharma Corp. (NGEN:TSX.V; NGENF:OTCQX) is making significant strides in the field of nerve damage and spinal cord injury treatments. Find out about the company's future plans and why Chen Lin of What is Chen Buying? What is Chen Selling? said he believes Nervgen could potentially become the next Eli Lilly.
Positive Phase 2 Clinical Trial Results Announced for Drug Treating Idiopathic Hypersomnia (06/10/2024)
Zevra Therapeutics Inc. (ZVRA:NASDAQ), a company specializing in rare disease therapeutics, has announced positive final results from its Phase 2 clinical trial evaluating the safety and tolerability of KP1077 for treating idiopathic hypersomnia.
Rare Disease Co. Presents Positive Phase 2 KP1077 Data (06/06/2024)
Zevra Therapeutics Inc. (ZVRA:NASDAQ) recently presented positive final results from its Phase 2 trial evaluating KP1077 in idiopathic hypersomnia (IH) patients at the SLEEP 2024 conference, according to a Roth MKM research note.
Co. Targets More Verticals in Safe Supply (06/05/2024)
This Canadian firm, with a streaming business model, intends to invest in two additional segments of the safe supply ecosystem. Here, learn more about this approach to reducing harms from illegal drugs.
More Archives
2024Aug Jul Jun May Apr Mar Feb Jan
2023Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2022Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2021Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
